StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses ASX health and biotechnology companies focused on fighting cancer.

Populating the expert panel this week is Tim Boreham, health & biotech journalist, Leslie Chong, CEO & managing director of Imugene (ASX:IMU) and Steven Yatomi-Clarke, CEO & managing director of Prescient Therapeutics (ASX:PTX).

The group discusses a range of topics, including appraising biotech stocks and valuing milestones, key development stages for oncology treatments, the importance of banking and M&A skills on biotech boards, key trends and investment hotspots and much more.

READ: Fighting the cancer battle, ASX small-cap edition

Read MoreAusbiotechBiotechDrug Development

Featured Companies

You might be interested in